If you are looking for small-cap ASX shares to buy, then read on.
Listed below are two that experts are tipping as buys and one that they believe investors should be selling, courtesy of The Bull.
Here's what they are recommending:
Images source: Getty Images
4DMedical Ltd (ASX: 4DX)
The team at Ord Minnett thinks that respiratory imaging technology company 4DMedical is a small-cap ASX share to sell now.
However, this isn't due to a lack of quality. The recommendation is based on valuation grounds after a very strong rise over the past 12 months. It explains:
4DX enjoyed a positive start to calendar year 2026 after the company announced UC San Diego Health had adopted its CT:VQ product. Also, the company completed a $150 million institutional placement to primarily accelerate the commercialisation of CT:VQ. The share price has risen from 32 cents on June 2, 2025 to trade at $3.16 on February 5, 2026. In our view, there's a growing disconnect between 4DX's valuation and the uncertainty around near term CT:VQ revenue generation. While we remain positive on 4DX's technology, we pull back to a sell recommendation on valuation grounds.
Legacy Minerals Holdings Ltd (ASX: LGM)
Over at Alto Capital, analysts think this mineral exploration company is a buy.
It notes that the company is due to release its scoping study for Mt Carrington in the coming months, which could be a positive catalyst for its shares. Alto Capital said:
This exploration company focuses on gold, silver and base metals targets in New South Wales, with its flagship Mt Carrington project located in the Lachlan Fold Belt. Recent funding has strengthened the balance sheet and supports ongoing drilling across priority targets. The company is also expected to release a revised scoping study for Mt Carrington in March, providing a key near term catalyst. While early stage exploration carries inherent geological risk, any success at Mt Carrington would be significant given LGM's modest market capitalisation.
Praemium Ltd (ASX: PPS)
This investment platform provider's shares could be a buy according to analysts at Ord Minnett.
It has been pleased with its performance in FY 2026 and believes the trend can continue thanks to its improving outlook. Ord Minnett explains:
PPS provides an investment platform to enable financial advisers to manage client accounts. The company's second quarter update in fiscal year 2026 revealed some encouraging trends, even if progress was uneven across its products. Improving inflows to the Powerwrap platform was a highlight, while Praemium SMA was impacted by a client transition. Overall, net inflows were solid and platform funds under administration of $32.5 billion were up 8 per cent and in line with expectations. We still see an improving outlook for PPS.
